FDA
-
-
-
-
-
-
-
FDA places PepGen's FREEDOM2 trial on partial clinical hold
-
-
-
-
-
-
-
PEPGEN reports 53.7% splicing correction in DM1 trial
-
-
-
-
-
-
-
PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
-
-
-
-
-
-
Shareholders of PepGen Should Contact Faruqi & Faruqi Before August 11, 2025 to Discuss Your Rights - PEPG
-
-
-
-
-
-
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
-
-
-
-
-
-
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PEPG
-
-
-
-
-
-
-
PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
322,208 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

